CERENIS THERAPEUTICS SA
Patent Owner
Stats
- 4 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Dec 19, 2013 most recent publication
Details
- 4 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 80 Total Citation Count
- Feb 14, 2000 Earliest Filing
- 7 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
6514523 Carrier particles for drug delivery and process for preparationFeb 14, 00Feb 04, 03[A61K, B01J, B32B]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2013/0337,041 CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USEAbandonedFeb 25, 13Dec 19, 13[A61K]
2011/0092,517 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related DiseasesAbandonedAug 13, 10Apr 21, 11[A61K, A61P]
2008/0275,007 CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USEAbandonedApr 21, 08Nov 06, 08[A61K, A61P]
2007/0269,503 Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereofAbandonedMay 16, 06Nov 22, 07[A61K]
2007/0048,823 Compositions and Methods for Producing Apolipoprotein Gene Products in Lactic Acid BacteriaAbandonedAug 25, 06Mar 01, 07[C07H, C12P, C12N, C07K]
2006/0128,656 Charged phospholipid compositions and methods for their useAbandonedJan 31, 06Jun 15, 06[A61K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.